사용자:순무/연습장
 | |
| 창립 | 1998 |
|---|---|
| 창립자 | Byoung Joo Gwag |
| 산업 분야 | Pharmaceutical |
| 본사 소재지 | South Korea |
| 웹사이트 | gntpharma.com/EN |
GNT Pharma (Korean: 주식회사 지엔티파마) is a South Korean pharmaceutical and chemical company headquartered in Giheung-gu, Yongin-si, Gyeonggi-do. It was established in 1998 by Byoung Joo Gwag. GNT Pharma is developing drugs targeting cerebrovascular diseases, degenerative brain diseases, and chronic inflammatory - respiratory diseases.
Pipelines
편집- Nelonemdaz: Nelonemdaz is the first "multi-target" neuroprotection drug designed to reduce brain damage after stroke or cardiac arrest.
- Crisdesalazine: Crisdesalazine is a multi-target drug that removes both free radicals and inflammation, which are proven contributors to Alzheimer’s disease and other neurodegenerative brain diseases.
- Flusalazine: A novel anti-inflammatory drug documented to be safe in cultured cells and animals and discovered using a ligand- and structure-based drug design to reduce the gastrointestinal side effects of aspirin and the granulocytopenia side effect of sulfasalazine.